Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. / Nauck, Michael A; El-Ouaghlidi, Andrea; Gabrys, Bartholomäus; Hücking, Katrin; Holst, Jens J; Deacon, Carolyn F; Gallwitz, Baptist; Schmidt, Wolfgang E; Meier, Juris J.

In: Regulatory Peptides, Vol. 122, No. 3, 2004, p. 209-17.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Nauck, MA, El-Ouaghlidi, A, Gabrys, B, Hücking, K, Holst, JJ, Deacon, CF, Gallwitz, B, Schmidt, WE & Meier, JJ 2004, 'Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.', Regulatory Peptides, vol. 122, no. 3, pp. 209-17. https://doi.org/10.1016/j.regpep.2004.06.020

APA

Nauck, M. A., El-Ouaghlidi, A., Gabrys, B., Hücking, K., Holst, J. J., Deacon, C. F., ... Meier, J. J. (2004). Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Regulatory Peptides, 122(3), 209-17. https://doi.org/10.1016/j.regpep.2004.06.020

Vancouver

Nauck MA, El-Ouaghlidi A, Gabrys B, Hücking K, Holst JJ, Deacon CF et al. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Regulatory Peptides. 2004;122(3):209-17. https://doi.org/10.1016/j.regpep.2004.06.020

Author

Nauck, Michael A ; El-Ouaghlidi, Andrea ; Gabrys, Bartholomäus ; Hücking, Katrin ; Holst, Jens J ; Deacon, Carolyn F ; Gallwitz, Baptist ; Schmidt, Wolfgang E ; Meier, Juris J. / Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. In: Regulatory Peptides. 2004 ; Vol. 122, No. 3. pp. 209-17.

Bibtex

@article{eb4ef4a0ab4b11ddb5e9000ea68e967b,
title = "Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.",
abstract = "AIMS/HYPOTHESIS: Since insulin secretion in response to exogenous gastric inhibitory polypeptide (GIP) is diminished not only in patients with type 2 diabetes, but also in their normal glucose-tolerant first-degree relatives, it was the aim to investigate the integrity of the entero-insular axis in such subjects. METHODS: Sixteen first-degree relatives of patients with type 2 diabetes (4 male, 12 female, age 50+/-12 years, BMI 26.1+/-3.8 kg/m(2)) and 10 matched healthy controls (negative family history, 6 male, 4 female, 45+/-13 years, 26.1+/-4.2 kg/m(2)) were examined with an oral glucose load (75 g) and an {"}isoglycaemic{"} intravenous glucose infusion. Blood was drawn over 240 min for plasma glucose (glucose oxidase), insulin, C-peptide, GIP and glucagon-like peptide 1 (GLP-1; specific immunoassays). RESULTS: The pattern of glucose concentrations could precisely be copied by the intravenous glucose infusion (p=0.99). Insulin secretion was stimulated significantly more by oral as compared to intravenous glucose in both groups (p<0.0001). The percent contribution of the incretin effect was similar in both groups (C-peptide: 61.9+/-5.4 vs. 64.4+/-5.8{\%}; p=0.77; insulin: 74.2+/-3.3 vs. 75.8+/-4.9; p=0.97; in first-degree relatives and controls, respectively). The individual responses of GIP and GLP-1 secretion were significantly correlated with each other (p=0.0003). The individual secretion of both GIP and GLP-1 was identified as a strong predictor of the integrated incremental insulin secretory responses as well as of the incretin effect. CONCLUSION/INTERPRETATION: Despite a lower insulin secretory response to exogenous GIP, incretin effects are similar in first-degree relatives of patients with type 2 diabetes and control subjects. This may be the result of a B cell secretory defect that affects stimulation by oral and intravenous glucose to a similar degree. Nevertheless, endogenous secretion of GIP and GLP-1 is a major determinant of insulin secretion after oral glucose.",
author = "Nauck, {Michael A} and Andrea El-Ouaghlidi and Bartholom{\"a}us Gabrys and Katrin H{\"u}cking and Holst, {Jens J} and Deacon, {Carolyn F} and Baptist Gallwitz and Schmidt, {Wolfgang E} and Meier, {Juris J}",
note = "Keywords: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Family; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Insulin; Male; Middle Aged; Peptide Fragments; Protein Precursors",
year = "2004",
doi = "10.1016/j.regpep.2004.06.020",
language = "English",
volume = "122",
pages = "209--17",
journal = "Regulatory Peptides",
issn = "0167-0115",
publisher = "Elsevier",
number = "3",

}

RIS

TY - JOUR

T1 - Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.

AU - Nauck, Michael A

AU - El-Ouaghlidi, Andrea

AU - Gabrys, Bartholomäus

AU - Hücking, Katrin

AU - Holst, Jens J

AU - Deacon, Carolyn F

AU - Gallwitz, Baptist

AU - Schmidt, Wolfgang E

AU - Meier, Juris J

N1 - Keywords: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Family; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Insulin; Male; Middle Aged; Peptide Fragments; Protein Precursors

PY - 2004

Y1 - 2004

N2 - AIMS/HYPOTHESIS: Since insulin secretion in response to exogenous gastric inhibitory polypeptide (GIP) is diminished not only in patients with type 2 diabetes, but also in their normal glucose-tolerant first-degree relatives, it was the aim to investigate the integrity of the entero-insular axis in such subjects. METHODS: Sixteen first-degree relatives of patients with type 2 diabetes (4 male, 12 female, age 50+/-12 years, BMI 26.1+/-3.8 kg/m(2)) and 10 matched healthy controls (negative family history, 6 male, 4 female, 45+/-13 years, 26.1+/-4.2 kg/m(2)) were examined with an oral glucose load (75 g) and an "isoglycaemic" intravenous glucose infusion. Blood was drawn over 240 min for plasma glucose (glucose oxidase), insulin, C-peptide, GIP and glucagon-like peptide 1 (GLP-1; specific immunoassays). RESULTS: The pattern of glucose concentrations could precisely be copied by the intravenous glucose infusion (p=0.99). Insulin secretion was stimulated significantly more by oral as compared to intravenous glucose in both groups (p<0.0001). The percent contribution of the incretin effect was similar in both groups (C-peptide: 61.9+/-5.4 vs. 64.4+/-5.8%; p=0.77; insulin: 74.2+/-3.3 vs. 75.8+/-4.9; p=0.97; in first-degree relatives and controls, respectively). The individual responses of GIP and GLP-1 secretion were significantly correlated with each other (p=0.0003). The individual secretion of both GIP and GLP-1 was identified as a strong predictor of the integrated incremental insulin secretory responses as well as of the incretin effect. CONCLUSION/INTERPRETATION: Despite a lower insulin secretory response to exogenous GIP, incretin effects are similar in first-degree relatives of patients with type 2 diabetes and control subjects. This may be the result of a B cell secretory defect that affects stimulation by oral and intravenous glucose to a similar degree. Nevertheless, endogenous secretion of GIP and GLP-1 is a major determinant of insulin secretion after oral glucose.

AB - AIMS/HYPOTHESIS: Since insulin secretion in response to exogenous gastric inhibitory polypeptide (GIP) is diminished not only in patients with type 2 diabetes, but also in their normal glucose-tolerant first-degree relatives, it was the aim to investigate the integrity of the entero-insular axis in such subjects. METHODS: Sixteen first-degree relatives of patients with type 2 diabetes (4 male, 12 female, age 50+/-12 years, BMI 26.1+/-3.8 kg/m(2)) and 10 matched healthy controls (negative family history, 6 male, 4 female, 45+/-13 years, 26.1+/-4.2 kg/m(2)) were examined with an oral glucose load (75 g) and an "isoglycaemic" intravenous glucose infusion. Blood was drawn over 240 min for plasma glucose (glucose oxidase), insulin, C-peptide, GIP and glucagon-like peptide 1 (GLP-1; specific immunoassays). RESULTS: The pattern of glucose concentrations could precisely be copied by the intravenous glucose infusion (p=0.99). Insulin secretion was stimulated significantly more by oral as compared to intravenous glucose in both groups (p<0.0001). The percent contribution of the incretin effect was similar in both groups (C-peptide: 61.9+/-5.4 vs. 64.4+/-5.8%; p=0.77; insulin: 74.2+/-3.3 vs. 75.8+/-4.9; p=0.97; in first-degree relatives and controls, respectively). The individual responses of GIP and GLP-1 secretion were significantly correlated with each other (p=0.0003). The individual secretion of both GIP and GLP-1 was identified as a strong predictor of the integrated incremental insulin secretory responses as well as of the incretin effect. CONCLUSION/INTERPRETATION: Despite a lower insulin secretory response to exogenous GIP, incretin effects are similar in first-degree relatives of patients with type 2 diabetes and control subjects. This may be the result of a B cell secretory defect that affects stimulation by oral and intravenous glucose to a similar degree. Nevertheless, endogenous secretion of GIP and GLP-1 is a major determinant of insulin secretion after oral glucose.

U2 - 10.1016/j.regpep.2004.06.020

DO - 10.1016/j.regpep.2004.06.020

M3 - Journal article

C2 - 15491793

VL - 122

SP - 209

EP - 217

JO - Regulatory Peptides

JF - Regulatory Peptides

SN - 0167-0115

IS - 3

ER -

ID: 8417334